Navigation Links
New treatment boosts muscle function in myasthenia gravis
Date:8/13/2007

ST. PAUL, Minn. - A new type of treatment significantly reduces the severity of muscle weakness in myasthenia gravis (MG), giving hope for a new class of drugs to treat neurological disorders, according to a study published in the August 14, 2007, issue of Neurology, the medical journal of the American Academy of Neurology.

The drug, oral EN101antisense, inhibits the production of acetylcholine esterase, which is an important enzyme in the function of the neuromuscular junction, where nerves connect with muscles. Antisense is a synthetic, short segment of DNA that locks onto a strand of mRNA and blocks production of specific proteins.

This is the first time weve been able to show that antisense is effective and safe when taken orally for a neurological disease, said study author Zohar Argov, MD, with Hadassah Hebrew University Medical Center in Jerusalem and member of the American Academy of Neurology. Oral delivery of antisense has long been sought after since it is expected to improve patient compliance because daily injections wont be needed.

People with myasthenia gravis have increased fatigue and reduced strength in their voluntary muscles. Symptoms may also include a drooping eyelid, double vision, difficulty in swallowing, or slurred speech. Myasthenia gravis is believed to affect 20 out of every 100,000 people.

For the study, 16 people with myasthenia gravis were given daily doses of oral EN101 antisense for four days and monitored for one month. Four of the people later took the drug for a month. The study found that oral antisense reduced disease severity by an average of 46 percent, with patients experiencing improved muscle function, improved swallowing time and the disappearance of a drooping eyelid. Side effects reported during the study were dryness of eyes and mouth.

Experts say this discovery may have implications beyond myasthenia gravis. Oral antisense may become another mode of therapy in neuromuscular disease and further study is needed, said Argov. However, these preliminary results should be evaluated with caution since this was an open label study.

Argov says further research is underway to look at the effects of this drug over a longer period of time.


'/>"/>

Contact: Angela Babb
ababb@aan.com
651-695-2789
American Academy of Neurology
Source:Eurekalert

Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Thyroid hormone treatment hastens recovery after cardiac surgery
4. Feeding channel created by malaria parasite - a new target for malaria treatments
5. Now umbilical cord helps in stroke treatment.
6. Now AIDS treatment comes dirt-cheap
7. Breast cancer treatment to be determined by gene test
8. Hemopurifier may revolutionise AIDS treatment
9. New drug helps boost cancer treatment
10. Antidepressants come in handy for patients on treatment for hepatitis, cancers and multiple sclerosis
11. Experimental treatment for Ebola Virus Shows promising results in mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... , ... After a year and a half of planning the Multiple Pathways of Recovery ... Pathways of Recovery Conference was held May 2 -4, 2016 at the Mystic Marriott ... together to explore the many pathways individuals use to get into and sustain their recovery. ...
(Date:5/27/2016)... ... 2016 , ... Two director-level employees of Horizon Blue Cross Blue Shield of ... 2016 honorees. The award recognizes businesswomen who excel in their fields and who ... the MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health and Theresa ...
(Date:5/27/2016)... NY (PRWEB) , ... May 27, 2016 , ... This ... of a stroke, which we as a society can control and change. , As ... occurs nearly every 40 seconds within the United States. Plus, with an estimated 129,000 ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed ... by inspiring human interest stories, courtesy of leaders in the nursing and health ... the industry, from leading advocates and associations—namely Jones & Bartlett Learning. , Jones ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports hinting at ... company to wait until March 2017 for an interest rate increase, according to Rajeev ... of Business. , “The Federal Open Market Committee (FOMC) dot charts are of interest ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... CAMBRIDGE, England , May 25, 2016 /PRNewswire/ ... genomics company employing the precision of circulating tumour ... oncology, today announces the appointment of Professor ... will provide medical leadership across the clinical development ... that Inivata,s products help deliver significant improvements in ...
(Date:5/24/2016)... 24, 2016 Cirujanos holandeses han ... a los médicos a compartir sus mejores prácticas por ... mundial. Profesionales médicos de Europa, África, Asia ... a la aplicación, que combina la transmisión en vivo ... seguro. Educación   "Imagine un médico ...
(Date:5/24/2016)... May 24, 2016  Diana Russell suffers from a ... from the inside out.  This disease has put her ... her children and grandchildren to leave her home.  Because ... family cannot haul the wheelchair.  So if there is ... and Diana is left to wait for the bus. ...
Breaking Medicine Technology: